| 1 |
31601523 | Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. | 2021 Aug |
1 |
| 2 |
28844372 | Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. | 2018 Jul |
1 |
| 3 |
29266182 | Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). | 2018 Mar 15 |
2 |
| 4 |
29688882 | Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. | 2018 Oct |
1 |
| 5 |
27052658 | A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). | 2016 May |
1 |
| 6 |
24759590 | Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. | 2014 May-Jun |
2 |